How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Description:
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Sponsor:
AstraZenecaContacts:
AstraZeneca Clinical Study Information Centerinformation.center@astrazeneca.com
1-877-240-9479
Government Study Link:
NCT06879041 - Click here to see study onClinicalTrials.gov
[225Ac]-AZD2284
Isotope(s):
Target(s):
- STEAP2
Ligand: Antibodies
